Matreya antibodies directed against ganglioside and globoside glycolipids

Several gangliosides have been found to have elevated expressions in tumour cells. Many therapeutic treatments of tumour cells are being investigated using antibodies to target cells that express these elevated levels of gangliosides.

Anti-ganglioside asialo GM₁ polyclonal antibodies (anti-GA1) from Matreya are useful in the identification of Ganglio-N-tetraosylceramide (asialo GM₁) and in immune-targeting cells expressing asialo GM1. Anti-GA1 has been shown to eliminate natural killer (NK) cell activity, which enhances the incidence of tumour take and growth. It also shows slight reactivity with monocytes, macrophages and foetal thymocytes.

It appears that the reduction in NK activity is due to membrane damage rather than to cytolytic membrane attack. Due to the inhibition of NK activity, anti-GA1 is being pursued as an anti-immunogenic treatment for use in bone marrow transplants and other similar applications. Anti-GA1 also suppresses voltage-gated calcium channels on the axonal terminals of motor nerves thereby blocking neuromuscular transmission.

Matreya has a range of monoclonal and polyclonal antibodies directed against the carbohydrate chains of ganglioside and globoside glycolipids. These antibodies are suitable for use in enzyme-linked immunosorbent assay (ELISA) and TLC immunoblotting applications.

The antibodies are quality tested by actual ELISA and TLC immunoblotting analysis and contain no preservatives. They are for research use only.